Multiple Sclerosis Resource Centre

Welcome to the Multiple Sclerosis Resource Centre. This website is intended for international healthcare professionals with an interest in Multiple Sclerosis. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Alemtuzumab for relapsing-remitting multiple sclerosis

Richard A Diaz, Sally Doss, Martyn J Burke, Elisabeth George, Amanda I Adler

The Lancet Neurology, Volume 13, Issue 9, September 2014, Pages 869–870

On May 28, 2014, the UK National Institute of Health and Care Excellence (NICE) published guidancerecommending alemtuzumab as an option, within its licence, for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Alemtuzumab, a monoclonal antibody directed against lymphocytes, was appraised under the Single Technology Appraisal process. The appraisal'sremit was to assess the clinical and cost effectiveness of alemtuzumab, within its licensed indication, for the treatment of RRMS. Genzyme, who manufacture alemtuzumab under the brand name Lemtrada, submitted clinical evidence and a health economic model that was critiqued by an independent Evidence Review Group from the University of Southampton. A NICE Appraisal Committee met twice on Oct 22, 2013, and Feb 18, 2014, to consider the evidence, to hear from clinical specialists, patient experts, and Genzyme, and to develop the guidance.

Search this site

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in MS research sign up to our e-alert.

Subscribe »

About the Editors

  • Prof Timothy Vartanian

    Timothy Vartanian, Professor at the Brain and Mind Research Institute and the Department of Neurology, Weill Cornell Medical College, Cornell...
  • Dr Claire S. Riley

    Claire S. Riley, MD is an assistant attending neurologist and assistant professor of neurology in the Neurological Institute, Columbia University,...
  • Dr Rebecca Farber

    Rebecca Farber, MD is an attending neurologist and assistant professor of neurology at the Neurological Institute, Columbia University, in New...

This online Resource Centre has been made possible by a donation from EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany.

Note that EMD Serono, Inc., has no editorial control or influence over the content of this Resource Centre. The Resource Centre and all content therein are subject to an independent editorial review.

The Grant for Multiple Sclerosis Innovation
supports promising translational research projects by academic researchers to improve understanding of multiple sclerosis (MS) for the ultimate benefit of patients.  For full information and application details, please click here

Journal Editor's choice

Recommended by Prof. Brenda Banwell

Causes of death among persons with multiple sclerosis

Gary R. Cutter, Jeffrey Zimmerman, Amber R. Salter, et al.

Multiple Sclerosis and Related Disorders, September 2015, Vol 4 Issue 5